The company filed a provisional patent application with the United States Patent and Trademark Office (USPTO) as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat central nervous system disorders.
This patent is an addition to Clearmind's robust intellectual property portfolio that includes patents for MEAI as a binge behavior regulator, as an alcoholic beverage substitute and others.
The patent application refers to novel proprietary combinations of MEAI and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™. It demonstrates Clearmind’s corporate mission to broaden the therapeutic psychedelic toolbox for patients with mental health disorders who await treatments with increased efficacy and safety while reducing cost.
Clearmind has a broad IP footprint in the psychedelic space with 24 patents in 14 patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India. The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's PEA compound for treating alcohol use disorder, cocaine addiction, and obesity and its related metabolic disorders.
Recent CMND News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/10/2024 08:01:10 PM
- Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product • GlobeNewswire Inc. • 05/10/2024 12:24:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2024 08:01:25 PM
- Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment • GlobeNewswire Inc. • 05/07/2024 11:46:00 AM
- Clearmind Applies to Cease Being a Reporting Issuer in Canada • GlobeNewswire Inc. • 04/30/2024 08:15:00 PM
- Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders • GlobeNewswire Inc. • 04/17/2024 11:49:00 AM
- Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders • GlobeNewswire Inc. • 04/10/2024 11:17:00 AM
- Clearmind Medicine CEO Issues Letter to Shareholders • GlobeNewswire Inc. • 04/09/2024 12:07:00 PM
- Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China • GlobeNewswire Inc. • 03/19/2024 11:55:00 AM
- Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial • GlobeNewswire Inc. • 03/13/2024 12:14:00 PM
- Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange • GlobeNewswire Inc. • 03/13/2024 11:30:00 AM
- Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder • GlobeNewswire Inc. • 02/23/2024 12:06:00 PM
- Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China • GlobeNewswire Inc. • 02/05/2024 12:51:00 PM
- Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center • GlobeNewswire Inc. • 02/01/2024 01:15:00 PM
- Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement • GlobeNewswire Inc. • 01/16/2024 04:19:34 PM
- Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement • GlobeNewswire Inc. • 01/11/2024 02:28:00 PM
- Clearmind Medicine Completed Type A Meeting with the FDA • GlobeNewswire Inc. • 01/10/2024 12:18:00 PM
- SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments • GlobeNewswire Inc. • 01/04/2024 12:18:00 PM
- Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments • GlobeNewswire Inc. • 01/04/2024 12:18:00 PM
- Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards • GlobeNewswire Inc. • 12/14/2023 01:26:00 PM
- Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment • GlobeNewswire Inc. • 12/05/2023 01:47:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • May 16, 2024 8:13 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM